Executive SummaryPresident William Bergman will retire from the Procter & Gamble subsidiary on June 30. President since 1987, he reports directly to P&G Group VP Malcolm Jozoff. In December 1988, Bergman was elected P&G's VP for Rich-Vicks. Bergman has been with Richardson-Vicks since 1950, holding a number of marketing and financial posts over the years. He also served as chairman of the Nonprescription Drug Manufacturers Association from 1987-1989. Acquired by P&G in 1985, Rich-Vicks employs 650 people.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.